Regenicin, Inc.
RGIN
$0.00
$0.000.00%
OTC PK
| 03/31/2023 | 12/31/2022 | 09/30/2022 | 06/30/2022 | 03/31/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 42.47% | 14.34% | -5.47% | -17.70% | -18.06% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 59.33% | 14.34% | -5.47% | -17.70% | -18.06% |
| Operating Income | -59.33% | -14.34% | 5.47% | 17.70% | 18.06% |
| Income Before Tax | -55.89% | -14.71% | 4.68% | -6.49% | -5.65% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -55.89% | -14.71% | 4.68% | -6.49% | -5.65% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -55.89% | -14.71% | 4.68% | -6.49% | -5.65% |
| EBIT | -59.33% | -14.34% | 5.47% | 17.70% | 18.06% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -48.84% | -12.77% | 6.25% | -4.88% | -4.88% |
| Normalized Basic EPS | -52.00% | -10.71% | 7.14% | 13.79% | 13.79% |
| EPS Diluted | -48.84% | -12.77% | 6.25% | -4.88% | -4.88% |
| Normalized Diluted EPS | -52.00% | -10.71% | 7.14% | 13.79% | 13.79% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |